The time-tradeoff (TTO) test is widely used to measure quality of life for different health states. Subjects are asked to equate the value of living a given period in an inferior health state to the value of living a shorter period in good health. Applications of TTOs have been criticized based on the fact that the value of future life duration is taken as the future life duration itself. The authors show that for a health state in which a subject does not want to live longer than a specified amount of time, subjects' responses do not comply with the assumption that the value of the period in inferior health is equated to the value of the shorter period in good health. Actually, preference reversals with respect to such a health state point to the use of a proportional heuristic in the TTO test. Comparisons of the TTO test in these subjects with category scaling and difference measurements also favor a proportional inter pretation of the TTO test. In tests based on conjoint measurement, these subjects also appear to use a proportional heuristic. Consequences of the use of the TTO test and conjoint measurement in quality-of-life models are discussed.

Background: Catestatin is a chromogranin A-derived peptide with a wide spectrum of biological activities, such as inhibiting catecholamine release, decreasing blood pressure, stimulating histamine release, reducing beta-adrenergic stimulation, and regulating oxidative stress.Objectives: The aims of our study were to determine serum catestatin concentrations in obese children and adolescents in regard to presence or absence of metabolic syndrome (MS) and to evaluate the possible relations between catestatin levels and other cardiovascular risk factors.Subjects: Ninety-two obese subjects with a body mass index z score > 2, aged 10 to 18 years, and 39 healthy, normal weight controls were enrolled in the study.Methods: Serum catestatin concentrations were measured using an enzyme-linked immunosorbent assay.Results: Significantly lower serum catestatin concentrations were recorded in the group of obese subjects compared with a control group (10.03 ± 5.05 vs 13.13 ± 6.25 ng/mL, P = 0.004). Further analyses revealed significantly lower catestatin concentrations in the subgroup of obese patients with MS (9.02 ± 4.3 vs 10.54 ± 5.36 vs 13.13 ± 6.25, P = 0.008).Serum catestatin concentrations were significantly negatively correlated with diastolic blood pressure (r = −0.253, P = 0.014), homeostatic model assessment of insulin resistance (r = −0.215, P = 0.037) and high sensitivity C-reactive protein (r = −0.208, P = 0.044). Conclusions:To the best of our knowledge, this study is the first to report catestatin concentrations in obese children and adolescents and their possible relations with MS and cardiovascular risk factors in a pediatric population. Obese subjects with MS have lower serum catestatin concentrations than obese subjects without MS and controls. K E Y W O R D Sadolescents, catestatin, children, metabolic syndrome, obesity

Assessment of individual preferences by the TTO in this patient group is feasible and reliable. Therefore, the TTO can be used in clinical settings to elicit treatment preferences of women proven or suspected to have a genetic predisposition to breast cancer.

There is a need to give patients more information, especially about prophylactic mastectomy and among gene carriers. Beneficial effects were observed irrespective of whether genetic status was known, suggesting that information concerning treatment options should be made available as soon as DNA testing begins. The better psychological outcomes of women with stronger desires to participate may arise because the desire to participate is characteristic of emotional stability.

Cataract is a rare manifestation of ocular complication at an early phase of T1DM in the pediatric population. The pathophysiological mechanism of early diabetic cataract has not been fully understood; however, there are many theories about the possible etiology including osmotic damage, polyol pathway, and oxidative stress. The prevalence of early diabetic cataract in the population varies between 0.7 and 3.4% of children and adolescents with T1DM. The occurrence of diabetic cataract in most pediatric patients is the first sign of T1DM or occurs within 6 months of diagnosis of T1DM. Today, there are many experimental therapies for the treatment of diabetic cataract, but cataract surgery continues to be a gold standard in the treatment of diabetic cataract. Since the cataract is the leading cause of visual impairment in patients with T1DM, diabetic cataract requires an initial screening as well as continuous surveillance as a measure of prevention and this should be included in the guidelines of pediatric diabetes societies.